Sepio Capital LP Purchases 130 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sepio Capital LP raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,036 shares of the medical research company’s stock after purchasing an additional 130 shares during the quarter. Sepio Capital LP’s holdings in Thermo Fisher Scientific were worth $2,100,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Howard Capital Management Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. lifted its holdings in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after buying an additional 225,568 shares during the period. EP Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 8.3% in the 3rd quarter. EP Wealth Advisors LLC now owns 16,236 shares of the medical research company’s stock valued at $10,043,000 after buying an additional 1,245 shares during the last quarter. National Bank of Canada FI raised its position in shares of Thermo Fisher Scientific by 66.9% during the third quarter. National Bank of Canada FI now owns 646,692 shares of the medical research company’s stock worth $400,024,000 after acquiring an additional 259,123 shares during the last quarter. Finally, Zacks Investment Management boosted its holdings in Thermo Fisher Scientific by 12.9% in the third quarter. Zacks Investment Management now owns 45,733 shares of the medical research company’s stock valued at $28,289,000 after acquiring an additional 5,236 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TMO shares. Bank of America dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Scotiabank upped their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research report on Friday, January 10th. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research report on Friday, January 31st. Finally, Wells Fargo & Company boosted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $437.71 on Friday. The company has a market cap of $165.13 billion, a PE ratio of 26.48, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $437.22 and a 52 week high of $627.88. The business has a 50 day moving average price of $532.01 and a 200-day moving average price of $547.47.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.